Navigation Links
Takeda Responds to Verdict in Diabetes Drug Case
Date:4/26/2013

DEERFIELD, Ill., April 26, 2013 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A., Inc. announced today that in the case of Jack Cooper et al. v. Takeda Pharmaceuticals America, Inc., et al., No. CGC-12-518535 the jury found in favor of the plaintiffs and awarded a total of $6.5 million in damages. Takeda has filed motions asking the judge to rule in favor of the company as a matter of law and is considering its options, including a possible appeal if the motions are denied. The trial began on February 19 in Los Angeles before Judge Kenneth R. Freeman .

"Takeda respectfully disagrees with the jury's verdict," said Kenneth D. Greisman , senior vice president, general counsel and secretary, Takeda Pharmaceuticals U.S.A., Inc. "Takeda empathizes with patients like Mr. Cooper, but we believe the evidence did not support a finding that ACTOS caused his bladder cancer.  We also believe we demonstrated that Takeda acted responsibly with regard to ACTOS. We promptly disclosed ACTOS safety data to the U.S. Food & Drug Administration and other regulatory authorities and provided updated product information to health care professionals and patients."

The company is confident in the therapeutic benefits of ACTOS (pioglitazone HCl) and its importance as a treatment for type 2 diabetes.

"Patient safety is a critical priority for Takeda," said Greisman. "We plan to vigorously defend the company against future lawsuits."

Indication for ACTOS
ACTOS (pioglitazone) is a prescription medicine used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. ACTOS is not for the treatment of type 1 "juvenile" diabetes or diabetic ketoacidosis (increased ketones in blood or urine).

Important Safety Informati
'/>"/>

SOURCE Takeda Pharmaceuticals U.S.A., Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Takeda Launches New Subsidiary in Ecuador
2. Takeda lanza nueva subsidiaria en Ecuador
3. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
4. Takeda presenta la richiesta di autorizzazione allimmissione in commercio nellUnione Europea per Vedolizumab nella colite ulcerosa moderata-grave e nella malattia di Crohn
5. Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohns Disease in the European Union
6. Takeda and Resolve Therapeutics Enter Autoimmune Partnership
7. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
8. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
9. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
10. Takeda Completes its Russian Pharmaceutical Manufacturing Facility
11. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... used on patients in order to treat dental impairments, ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... received commitments from institutional investors to purchase an aggregate ... in an at-the-market registered direct offering, led by a ... into definitive purchase agreements with these investors pursuant to ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
(Date:4/24/2014)... professor in the new Institute for Biomedical Sciences ... $2.83 million federal grant to develop novel therapeutics ... grant from the Eunice Kennedy Shriver National Institute ... National Institutes of Health will support Plemper,s drug ... at least one distinct alternative compound. , Infections ...
(Date:4/24/2014)... to give than to receive at least if you,re ... , The study found that 15- and 16-year-olds who find ... family members, are less likely to become depressed than those ... the money for themselves. , The researchers detail their findings ... . , The study focused on the ventral striatum, a ...
(Date:4/24/2014)... pH1N1 virus caused the first flu pandemic in the ... and killed more than 50 people in the country. ... flu epidemics (winter/spring seasons). , Infections with influenza ... World Health Organization has recommended Tamiflu for treatment of ... this drug is that it targets viral proteins which ...
(Date:4/23/2014)... Moffitt Cancer Center researchers say clinical trials for ... leukemia (AML) are very promising. Patients treated with ... and daunorubicin, are showing better responses than patients ... , "Acute myeloid leukemia is an aggressive ... success, especially in older patients," explained Jeffrey Lancet, ...
(Date:4/23/2014)... to high-energy particles, simulating conditions astronauts would face on ... and slower reaction times, even when the radiation exposure ... impairments which affected a large subset, but far ... linked to protein changes in the brain, the scientists ... humans, suggest it may be possible to develop a ...
Breaking Medicine News(10 mins):Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3
... in the cereal category as they provide fibre beta glucan ... health-conscious consumers. So there is news to cheer now as ... called beta-glucan in their diets.,This variety of oats has been ... University (NDSU) scientists., ,Beta-glucan can help lower blood levels ...
... A new study has found that at high doses, ... result in liver damage, leading to significant health risks. ... University of Toronto, results of which can be found ... ,Previous studies have demonstrated the anti-oxidant effects of ...
... found out that retinal examination of a child, to determine the ... of abuse. // This was discussed in the American Academy of ... is a light sensitive tissue located behind the eye. Any rupture ... the result is bleeding or retinal hemorrhage. , A ...
... a molecular computer, which uses enzymes to perform calculations ... release of drugs.// ,Itamar Willner, who built ... Jerusalem in Israel, said the enzyme-powered computers could have ... future, be implanted into humans. ,The researchers ...
... California was slapped with four additional law suits, after the ... miserably. // ,Orange county Superior court has ... of patients who died just waiting for the transplants; the ... ,The liver transplant program transparent to gross mismanagement has to ...
... of doctors at the U.S. military prison in Guantanamo ... strike) through insertion of feeding tubes // through their ... who claim that such practices violate the fundamental principles ... are being subjected to harsh interrogations, targeted at extension ...
Cached Medicine News:Health News:Retinal Hemorrhage: No More a Sure Sign of Child Abuse 2Health News:Medical Ethics Violated By Prison Officials In Guantanamo Bay 2
The INSIGNIA® pacing systems allow the physician to provide customized adaptive-rate pacing therapy to meet individual patient needs....
... less than thirty pounds, the EUB 405 ... quality. Compatible with a wide range of ... solution for a variety of clinical settings. ... easy to operate. It includes an alphanumeric ...
... The HI VISION 6500 ... offers advanced clinical imaging, enhanced ... flexibility, all in robust and ... a better clinical solution in ...
... The PENTAX FG-36UX provides a wide range ... It is also possible to obtain a clear ... Flow Mapping and Color Flow Angio. An accessory ... has improved. Those feature make it possible for ...
Medicine Products: